{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"description":"An adverse event was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020.","groups":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"Pembrolizumab+Pomalidomide+Dexamethasone"},{"description":"Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"Standard of Care (SOC) Pomalidomide+Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received.","reportingStatus":"POSTED","timeFrame":"Up to approximately 54 months","title":"Participants Discontinuing Study Investigational Product Due to an AE","type":"SECONDARY","unitOfMeasure":"Participants"}